Desvenlafaxine Tablet, Extended Release
Product Images NDC 50090-5293

7 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 50090-5293). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Desvenlafaxine Structure1)

Structure (Desvenlafaxine Structure1)
Chemical structure diagram of Desvenlafaxine Succinate, showing its molecular configuration including phenol group, cyclohexane ring, nitrogen-containing side chain, and succinate moiety with associated water molecule.*
FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

Figure 1 (Desvenlafaxine Figure1)
A pharmacokinetic chart depicting geometric mean ratios with 90% confidence intervals for Cmax and AUC variables relative to reference across varying degrees of renal and hepatic impairment, as well as population demographics including gender and age groups (65-75 years and above 75 years). The x-axis shows change relative to reference from 0.5 to 3.5, with data points and confidence bars illustrating variability in drug exposure for Desvenlafaxine.*
FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

Figure 2 (Desvenlafaxine Figure2)
A pharmacokinetic chart illustrating the geometric mean ratio with 90% confidence interval for Cmax and AUC changes due to CYP3A4 inhibitor Ketoconazole. The x-axis shows the change relative to reference, ranging from 0.5 to 2, with data points for Cmax near 1.08 and AUC near 1.43.*
FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

Figure 3 (Desvenlafaxine Figure3)
A chart showing the geometric mean ratio (90% confidence interval) of pharmacokinetic parameters (Cmax and AUC) for Desvenlafaxine with interacting drugs. It includes data for various CYP substrates like Desipramine, Midazolam, Tamoxifen, and Aripiprazole, comparing different dosages of Desvenlafaxine and their impact on these pharmacokinetic measures relative to reference values.*
FDA Label Image

Figure 4 (Desvenlafaxine Image4)

Figure 4 (Desvenlafaxine Image4)
A line graph comparing estimated proportion of patients with relapse (%) over time (days from randomization) between Desvenlafaxine Extended-Release Tablets 50 mg and placebo. The graph shows a lower relapse rate in patients treated with Desvenlafaxine compared to placebo across approximately 180 days.*
FDA Label Image

Figure 5 (Desvenlafaxine Image5)

Figure 5 (Desvenlafaxine Image5)
A line graph depicting the estimated proportion of patients with relapse (%) over time (days from randomization) comparing Desvenlafaxine Extended-Release Tablets and placebo. The x-axis represents time to relapse in days, ranging from 0 to 180, and the y-axis shows the estimated proportion of patients with relapse from 0 to 50%. The graph contains two lines: one for Desvenlafaxine Extended-Release Tablets and a higher one for placebo, illustrating differing relapse rates over time.*
FDA Label Image

Label Image (Lbl500905293)

Label Image (Lbl500905293)
Desvenlafaxine 50 mg extended-release tablets label from A-S Medication Solutions. The label indicates oral administration with 30 tablets per bottle, designated for unit-of-use. Includes storage instructions to keep between 68 and 77 degrees Fahrenheit. Also displays the NDC 50090-5293-0 and contains a barcode with a QR code for dosage package insert access.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.